Rebif® (interferon beta-1a) – PRODUCT INFORMATION

Rebif is approved by the FDA to treat relapsing-remitting multiple sclerosis (MS), to slow the progression of physical disability, to reduce the frequency of flare-ups, and to treat the activity and area of brain lesions on magnetic resonance imaging (MRI).*

For more information, please visit MS LifeLines^® or download the full prescribing information.

*The exact correlation between MRI findings and the current or future clinical status of patients, including disability progression, is unknown.

Rebif and MS LifeLines are registered trademarks of EMD Serono, Inc. or its affiliates.